Catalyst overview
Research summary
This catalyst tracks a Phase 2b data readout for Danicamtiv in Genetic / familial dilated cardiomyopathy (DCM). The expected timing is based on the latest available company guidance and may change.
KINSHIP-DCM trial. 03/17/26:- ACC.26 presentation. 06/11/26:- KINSHIP-DCM trial ongoing; Phase 2b topline data in H1 2027 and intended to inform Phase 3 design. 08/12/26:- KINSHIP-DCM Cohort 1 enrolled. Ph3 enrollment underway. Ph2b topline data expected in H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.